{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:50Z","timestamp":1791676130759,"version":"4.3.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1007\/s00203-026-05234-5","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:32:46Z","timestamp":1791667966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elevated in vitro activity of ibrexafungerp against azole-resistant Candida isolates from Vulvovaginal Candidiasis (VVC): a multicentric study from India"],"prefix":"10.1007","volume":"209","author":[{"given":"Preeti","family":"Lather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragini","family":"Tilak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Mahor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Khuraijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradip Kumar","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaprakash M.","family":"Rudramurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shristi","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabnam","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyolakshmi","family":"Ningthoujam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushan","family":"Subba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anup","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"key":"5234_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/1477-7525-11-169","volume":"11","author":"S Aball\u00e9a","year":"2013","unstructured":"Aball\u00e9a S, Guelfucci F, Wagner J, Khemiri A, Dietz JP, Sobel J, Toumi M (2013) Subjective health status and health-related quality of life among women with Recurrent Vulvovaginal Candidosis (RVVC) in Europe and the USA. Health Qual Life Outcomes 11:169. https:\/\/doi.org\/10.1186\/1477-7525-11-169","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"5234_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejogrb.2008.12.020","volume":"144","author":"A Ahmad","year":"2009","unstructured":"Ahmad A, Khan AU (2009) Prevalence of Candida species and potential risk factors for vulvovaginal candidiasis in Aligarh, India. Eur J Obstet Gynecol Reprod Biol 144(1):68\u201371. https:\/\/doi.org\/10.1016\/j.ejogrb.2008.12.020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"5234_CR3","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01324-23","author":"AM Aldejohann","year":"2024","unstructured":"Aldejohann AM, Menner C, Thielemann N, Martin R, Walther G, Kurzai O (2024) In vitro activity of ibrexafungerp against clinically relevant echinocandin-resistant Candida strains. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.01324-23","journal-title":"Antimicrob Agents Chemother"},{"key":"5234_CR4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02136-19","author":"MC Arendrup","year":"2020","unstructured":"Arendrup MC, J\u00f8rgensen KM, Hare RK, Chowdhary A (2020) In vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST methodology and comparison with activity against C. albicans and C. glabrata and with the activities of six comparator agents. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.02136-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"5234_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1067\/mob.2002.125897","volume":"187","author":"TGM Bauters","year":"2002","unstructured":"Bauters TGM, Dhont MA, Temmerman MIL, Nelis HJ (2002) Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol 187(3):569\u2013574. https:\/\/doi.org\/10.1067\/mob.2002.125897","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"5234_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/antibiotics9060312","volume":"9","author":"S Bhattacharya","year":"2020","unstructured":"Bhattacharya S, Sae-Tia S, Fries BC (2020) Candidiasis and Mechanisms of Antifungal Resistance. Antibiot (Basel Switzerland) 9(6):312. https:\/\/doi.org\/10.3390\/antibiotics9060312","journal-title":"Antibiot (Basel Switzerland)"},{"key":"5234_CR7","unstructured":"BREXAFEMME\u00ae (ibrexafungerp tablets), for oral use. Product Insert. Available from: https:\/\/www.brexafemme.com\/prescribinginformation. Accessed August 13, (2022). (n.d.). (n.d.)"},{"key":"5234_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fmed.2018.00028","volume":"5","author":"M Cavalheiro","year":"2018","unstructured":"Cavalheiro M, Teixeira MC (2018) Candida Biofilms: Threats, Challenges, and Promising Strategies. Front Med 5:28. https:\/\/doi.org\/10.3389\/fmed.2018.00028","journal-title":"Front Med"},{"issue":"5","key":"5234_CR9","doi-asserted-by":"publisher","first-page":"e0325125","DOI":"10.1128\/spectrum.03251-25","volume":"14","author":"Y Chen","year":"2026","unstructured":"Chen Y, Lu L, Wang Q, Luo X, Gao J, Ying C (2026) Epidemiology of vulvovaginal candidiasis in China: a six-year retrospective single-center study from a tertiary obstetrics and gynecology hospital in Shanghai. Microbiol Spectr 14(5):e0325125 Advance online publication. https:\/\/doi.org\/10.1128\/spectrum.03251-25","journal-title":"Microbiol Spectr"},{"key":"5234_CR10","volume-title":"M27 Reference method for broth dilution antifungal susceptibility testing of yeasts","author":"CLSI","year":"2017","unstructured":"CLSI (2017) M27 Reference method for broth dilution antifungal susceptibility testing of yeasts, 4th edn. Clinical and Laboratory Standard Institute, Wayne (PA). https:\/\/clsi.org\/shop\/standards\/m27\/","edition":"4"},{"issue":"5","key":"5234_CR11","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/mmy\/myz083","volume":"58","author":"MR Davis","year":"2020","unstructured":"Davis MR, Donnelley MA, Thompson GR (2020) Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol 58(5):579\u2013592. https:\/\/doi.org\/10.1093\/mmy\/myz083","journal-title":"Med Mycol"},{"issue":"11","key":"5234_CR12","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","volume":"18","author":"DW Denning","year":"2018","unstructured":"Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R (2018) Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis 18(11):e339\u2013e347. https:\/\/doi.org\/10.1016\/S1473-3099(18)30103-8","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"5234_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1136\/sti.78.4.308-a","volume":"78","author":"L Dorrell","year":"2002","unstructured":"Dorrell L, Edwards A (2002) Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex Transm Infect 78(4):308\u2013309. https:\/\/doi.org\/10.1136\/sti.78.4.308-a","journal-title":"Sex Transm Infect"},{"key":"5234_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2022.105696","volume":"170","author":"A Esfahani","year":"2022","unstructured":"Esfahani A, Omran AN, Salehi Z, Shams-Ghahfarokhi M, Ghane M, Eybpoosh S, Razzaghi-Abyaneh M (2022) Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: comparison between recurrent and non-recurrent infections. Microb Pathog 170:105696. https:\/\/doi.org\/10.1016\/j.micpath.2022.105696","journal-title":"Microb Pathog"},{"issue":"5","key":"5234_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jof10050362","volume":"10","author":"A Espinel-Ingroff","year":"2024","unstructured":"Espinel-Ingroff A, Wiederhold NP (2024) A mini-review of in vitro data for Candida species, including C. auris, isolated during clinical trials of three new antifungals: fosmanogepix, ibrexafungerp, and rezafungin. J Fungi 10(5):362. https:\/\/doi.org\/10.3390\/jof10050362","journal-title":"J Fungi"},{"key":"5234_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.fgb.2021.103575","volume":"153","author":"N Fattouh","year":"2021","unstructured":"Fattouh N, Hdayed D, Geukgeuzian G, Tokajian S, Khalaf RA (2021) Molecular mechanism of fluconazole resistance and pathogenicity attributes of Lebanese Candida albicans hospital isolates. Fungal Genet Biol 153:103575. https:\/\/doi.org\/10.1016\/j.fgb.2021.103575","journal-title":"Fungal Genet Biol"},{"key":"5234_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.642358","volume":"11","author":"A Gamal","year":"2021","unstructured":"Gamal A, Chu S, McCormick TS, Borroto-Esoda K, Angulo D, Ghannoum MA (2021) Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata. Front Cell Infect Microbiol 11:642358. https:\/\/doi.org\/10.3389\/fcimb.2021.642358","journal-title":"Front Cell Infect Microbiol"},{"issue":"6","key":"5234_CR18","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3109\/1040841X.2015.1091805","volume":"42","author":"B Gon\u00e7alves","year":"2016","unstructured":"Gon\u00e7alves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S (2016) Vulvovaginal candidiasis: epidemiology, microbiology and risk factors. Crit Rev Microbiol 42(6):905\u2013927. https:\/\/doi.org\/10.3109\/1040841X.2015.1091805","journal-title":"Crit Rev Microbiol"},{"issue":"8\u20139","key":"5234_CR19","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.micinf.2009.04.018","volume":"11","author":"F Hasan","year":"2009","unstructured":"Hasan F, Xess I, Wang X, Jain N, Fries BC (2009) Biofilm formation in clinical Candida isolates and its association with virulence. Microbes Infect 11(8\u20139):753\u2013761. https:\/\/doi.org\/10.1016\/j.micinf.2009.04.018","journal-title":"Microbes Infect"},{"issue":"3","key":"5234_CR20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.105579","volume":"18","author":"SC Hazarika","year":"2026","unstructured":"Hazarika SC, Baishya L, Dutta R, Sarma K, Chakravarty M, Hazarika HN (2026) Vulvovaginal candidiasis among patients attending the Gynecology Outpatient Department (GOPD) and STD Clinic with special reference to their antifungal susceptibility and the genetic diversity of non-albicans Candida in a tertiary care hospital. Cureus 18(3):e105579. https:\/\/doi.org\/10.7759\/cureus.105579","journal-title":"Cureus"},{"issue":"7","key":"5234_CR21","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1111\/jog.15267","volume":"48","author":"L Jafarzadeh","year":"2022","unstructured":"Jafarzadeh L, Ranjbar M, Nazari T, Naeimi Eshkaleti M, Aghaei Gharehbolagh S, Sobel JD, Mahmoudi S (2022) Vulvovaginal candidiasis: an overview of mycological, clinical, and immunological aspects. J Obstet Gynaecol Res 48(7):1546\u20131560. https:\/\/doi.org\/10.1111\/jog.15267","journal-title":"J Obstet Gynaecol Res"},{"issue":"3","key":"5234_CR22","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/jof7030163","volume":"7","author":"S Jallow","year":"2021","unstructured":"Jallow S, Govender NP (2021) Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor. J fungi (Basel Switzerland) 7(3):163. https:\/\/doi.org\/10.3390\/jof7030163","journal-title":"J fungi (Basel Switzerland)"},{"key":"5234_CR23","doi-asserted-by":"publisher","DOI":"10.31083\/j.ceog5103077","author":"B Jannati","year":"2024","unstructured":"Jannati B, Pourdad A, Izadjoo A, Zarrinfar H, Najafzadeh MJ, Fata A (2024) The prevalence of non-albicans Candida and Candida mixed-species in vulvovaginal candidiasis in Northeast Iran. Clin Exp Obstet Gynecol. https:\/\/doi.org\/10.31083\/j.ceog5103077","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"10","key":"5234_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jof8101106","volume":"8","author":"KM J\u00f8rgensen","year":"2022","unstructured":"J\u00f8rgensen KM, Astvad KMT, Hare RK, Arendrup MC (2022) EUCAST Ibrexafungerp MICs and wild-type upper limits for contemporary Danish yeast isolates. J Fungi 8(10):1106. https:\/\/doi.org\/10.3390\/jof8101106","journal-title":"J Fungi"},{"issue":"4","key":"5234_CR25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12223-020-00785-6","volume":"65","author":"A Kumar","year":"2020","unstructured":"Kumar A, Nair R, Kumar M, Banerjee A, Chakrabarti A, Rudramurthy SM, Bagga R, Gaur NA, Mondal AK, Prasad R (2020) Assessment of antifungal resistance and associated molecular mechanism in Candida albicans isolates from different cohorts of patients in North Indian state of Haryana. Folia Microbiol 65(4):747\u2013754. https:\/\/doi.org\/10.1007\/s12223-020-00785-6","journal-title":"Folia Microbiol"},{"issue":"5","key":"5234_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02611-18","volume":"63","author":"EL Larkin","year":"2019","unstructured":"Larkin EL, Long L, Isham N, Borroto-Esoda K, Barat S, Angulo D, Wring S, Ghannoum M (2019) A novel 1,3-beta-d-glucan inhibitor, ibrexafungerp (formerly SCY-078), shows potent activity in the lower pH environment of vulvovaginitis. Antimicrob Agents Chemother 63(5):e02611-18. https:\/\/doi.org\/10.1128\/AAC.02611-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"5234_CR27","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1099\/00221287-145-10-2701","volume":"145","author":"P Marichal","year":"1999","unstructured":"Marichal P, Koymans L, Willemsens S, Bellens D, Verhasselt P, Luyten W, Borgers M, Ramaekers FCS, Odds FC, Vanden Bossche H (1999) Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (Reading, England) 145(10):2701\u20132713. https:\/\/doi.org\/10.1099\/00221287-145-10-2701","journal-title":"Microbiology (Reading, England)"},{"issue":"5","key":"5234_CR28","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1086\/322600","volume":"33","author":"B Mathema","year":"2001","unstructured":"Mathema B, Cross E, Dun E, Park S, Bedell J, Slade B, Williams M, Riley L, Chaturvedi V, Perlin DS (2001) Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect diseases: official publication Infect Dis Soc Am 33(5):E23\u2013E27. https:\/\/doi.org\/10.1086\/322600","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"6","key":"5234_CR29","doi-asserted-by":"publisher","first-page":"915.e5","DOI":"10.1016\/j.cmi.2021.02.006","volume":"27","author":"A Mesquida","year":"2021","unstructured":"Mesquida A, Vicente T, Reigadas E, Palomo M, S\u00e1nchez-Carrillo C, Mu\u00f1oz P, Guinea J, Escribano P (2021) In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures. Clin Microbiol Infect 27(6):915.e5-915.e8. https:\/\/doi.org\/10.1016\/j.cmi.2021.02.006","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"5234_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2026.107870","volume":"67","author":"MJ Morelo","year":"2026","unstructured":"Morelo MJ, Firacative C, Garcia-Effron G, G\u00f3mez BL, Ceballos-Garzon A (2026) Wild-type MIC distributions and epidemiological cut-off values for ibrexafungerp, manogepix, and rezafungin against WHO fungal priority pathogens. Int J Antimicrob Agents 67(9):107870. https:\/\/doi.org\/10.1016\/j.ijantimicag.2026.107870","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"5234_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/cid\/civ353","volume":"61","author":"CA Muzny","year":"2015","unstructured":"Muzny CA, Schwebke JR (2015) Biofilms: An Underappreciated Mechanism of Treatment Failure and Recurrence in Vaginal Infections. Clin Infect diseases: official publication Infect Dis Soc Am 61(4):601\u2013606. https:\/\/doi.org\/10.1093\/cid\/civ353","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"issue":"1","key":"5234_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mycmed.2025.101590","volume":"36","author":"TK Ngouana","year":"2026","unstructured":"Ngouana TK, Dougue AN, Ngouana V, Fouemene Tsayem R, Mahamat YH, Fekam Boyom F F, Ranque S (2026) Vulvo-vaginal candidiasis at the Zion Clinical Laboratory (Yaounde-Cameroon): risk factors, species distribution and antifungal susceptibility testing. J Mycol Med 36(1):101590. https:\/\/doi.org\/10.1016\/j.mycmed.2025.101590","journal-title":"J Mycol Med"},{"issue":"11","key":"5234_CR33","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01692-19","volume":"63","author":"NS Nunnally","year":"2019","unstructured":"Nunnally NS, Etienne KA, Angulo D, Lockhart SR, Berkow EL (2019) In vitro activity of ibrexafungerp, a novel glucan synthase inhibitor against Candida glabrata isolates with FKS mutations. Antimicrob Agents Chemother 63(11):e01692-19. https:\/\/doi.org\/10.1128\/AAC.01692-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5234_CR34","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0889-8545(03)00083-4","volume":"30","author":"P Nyirjesy","year":"2003","unstructured":"Nyirjesy P, Sobel JD (2003) Vulvovaginal candidiasis. Obstet Gynecol Clin North Am 30(4):671\u2013684. https:\/\/doi.org\/10.1016\/S0889-8545(03)00083-4","journal-title":"Obstet Gynecol Clin North Am"},{"key":"5234_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioflm.2023.100162","volume":"6","author":"Y Pan","year":"2023","unstructured":"Pan Y, Sun Y, Chen L, Cheng Y, Jin P, Zhang W, Zheng L, Liu J, Zhou T, Xu Z, Li C, Kostoulias X, Watson CJ, McGiffin D, Peleg AY, Qu Y (2023) Candida causes recurrent vulvovaginal candidiasis by forming morphologically disparate biofilms on the human vaginal epithelium. Biofilm 6:100162. https:\/\/doi.org\/10.1016\/j.bioflm.2023.100162","journal-title":"Biofilm"},{"issue":"8","key":"5234_CR36","doi-asserted-by":"publisher","first-page":"248","DOI":"10.52403\/ijhsr.20250829","volume":"15","author":"P Paul","year":"2025","unstructured":"Paul P, Das P, Pandey N (2025) Vulvovaginal Candidiasis: Characterization of Etiologic Agent with Their Antifungal Susceptibility Pattern. Int J Health Sci Res 15(8):248\u2013254. https:\/\/doi.org\/10.52403\/ijhsr.20250829","journal-title":"Int J Health Sci Res"},{"issue":"1","key":"5234_CR37","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1128\/CMR.00013-11","volume":"25","author":"BM Peters","year":"2012","unstructured":"Peters BM, Jabra-Rizk MA, O\u2019May GA, Costerton JW, Shirtliff ME (2012) Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 25(1):193\u2013213. https:\/\/doi.org\/10.1128\/CMR.00013-11","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"5234_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/whr.2021.0065","volume":"3","author":"NA Phillips","year":"2022","unstructured":"Phillips NA, Bachmann G, Haefner H, Martens M, Stockdale C (2022) Topical Treatment of Recurrent Vulvovaginal Candidiasis: An Expert Consensus. Women\u2019s health Rep (New Rochelle N Y) 3(1):38\u201342. https:\/\/doi.org\/10.1089\/whr.2021.0065","journal-title":"Women\u2019s health Rep (New Rochelle N Y)"},{"key":"5234_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.906563","volume":"12","author":"G Quind\u00f3s","year":"2022","unstructured":"Quind\u00f3s G, Miranda-Cadena K, San-Mill\u00e1n R, Borroto-Esoda K, Cant\u00f3n E, Linares-Sicilia MJ, Hamprecht A, Montesinos I, Tortorano AM, Prigitano A, Vidal-Garc\u00eda M, Marcos-Arias C, Guridi A, Sanchez-Reus F, Machuca-B\u00e1rcena J, Rodr\u00edguez-Iglesias MA, Mart\u00edn-Mazuelos E, Castro-M\u00e9ndez C, L\u00f3pez-Soria L, Ruiz-Gait\u00e1n A, Fernandez-Rivero M, Lorenzo D, Capilla J, Rezusta A, Pem\u00e1n J, Guarro J, Pereira J, Pais C, Romeo O, Ezpeleta G, Jauregizar N, Angulo D, Eraso E (2022) In vitro antifungal activity of ibrexafungerp (SCY-078) against contemporary blood isolates from medically relevant species of Candida: a European study. Front Cell Infect Microbiol 12:906563. https:\/\/doi.org\/10.3389\/fcimb.2022.906563","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"5234_CR40","doi-asserted-by":"publisher","first-page":"72","DOI":"10.17511\/ijmrr.2015.i1.12","volume":"3","author":"R Rati","year":"2015","unstructured":"Rati R, Patel J, Rishi S (2015) Vulvovaginal Candidiasis and its Antifungal Susceptibility Pattern: Single center experience. Int J Med Res Rev 3(1):72\u201378. https:\/\/doi.org\/10.17511\/ijmrr.2015.i1.12","journal-title":"Int J Med Res Rev"},{"issue":"5","key":"5234_CR41","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1128\/JCM.43.5.2155-2162.2005","volume":"43","author":"SS Richter","year":"2005","unstructured":"Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43(5):2155\u20132162. https:\/\/doi.org\/10.1128\/JCM.43.5.2155-2162.2005","journal-title":"J Clin Microbiol"},{"key":"5234_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.544480","volume":"11","author":"C Rodr\u00edguez-Cerdeira","year":"2020","unstructured":"Rodr\u00edguez-Cerdeira C, Mart\u00ednez-Herrera E, Carnero-Gregorio M, L\u00f3pez-Barcenas A, Fabbrocini G, Fida M, El-Samahy M, Gonz\u00e1lez-Cesp\u00f3n JL (2020) Pathogenesis and clinical relevance of Candida biofilms in vulvovaginal candidiasis. Front Microbiol 11:544480. https:\/\/doi.org\/10.3389\/fmicb.2020.544480","journal-title":"Front Microbiol"},{"key":"5234_CR43","doi-asserted-by":"publisher","DOI":"10.25259\/JLP-2023-8-4-(1747)","author":"SM Rudresh","year":"2023","unstructured":"Rudresh SM, Nikhi V, Shakuntala PN, Hansraj C, Karthik B, Tejaswini N, Shivaprakash MR (2023) Antifungal susceptibility profile of Candida species isolated from women with vulvovaginal candidiasis. J Lab Physicians. https:\/\/doi.org\/10.25259\/JLP-2023-8-4-(1747)","journal-title":"J Lab Physicians"},{"issue":"5","key":"5234_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/myc.70062","volume":"68","author":"V Sharma","year":"2025","unstructured":"Sharma V, Das S, Spruijtenburg B, de Groot T, Meijer E, Kaur H, Rudramurthy SM, Ghosh A (2025) Genotypic diversity and molecular basis of fluconazole resistance in Candida parapsilosis clinical isolates collected over 7 years in a tertiary-care hospital in North India. Mycoses 68(5):e70062. https:\/\/doi.org\/10.1111\/myc.70062","journal-title":"Mycoses"},{"issue":"5","key":"5234_CR45","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.tim.2011.02.003","volume":"19","author":"S Silva","year":"2011","unstructured":"Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J (2011) Adherence and biofilm formation of non-Candida albicans Candida species. Trends Microbiol 19(5):241\u2013247. https:\/\/doi.org\/10.1016\/j.tim.2011.02.003","journal-title":"Trends Microbiol"},{"issue":"9577","key":"5234_CR46","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/S0140-6736(07)60917-9","volume":"369","author":"JD Sobel","year":"2007","unstructured":"Sobel JD (2007) Vulvovaginal candidosis. Lancet (London, England) 369(9577):1961\u20131971. https:\/\/doi.org\/10.1016\/S0140-6736(07)60917-9","journal-title":"Lancet (London, England)"},{"issue":"1","key":"5234_CR47","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","volume":"214","author":"JD Sobel","year":"2016","unstructured":"Sobel JD (2016) Recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 214(1):15\u201321. https:\/\/doi.org\/10.1016\/j.ajog.2015.06.067","journal-title":"Am J Obstet Gynecol"},{"key":"5234_CR48","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00181-23","author":"JD Sobel","year":"2023","unstructured":"Sobel JD (2023) Resistance to fluconazole of Candida albicans in vaginal isolates: a 10-year study in a clinical referral center. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00181-23","journal-title":"Antimicrob Agents Chemother"},{"key":"5234_CR49","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00562-21","author":"JD Sobel","year":"2021","unstructured":"Sobel JD, Borroto-Esoda K, Azie N, Angulo D (2021) In vitro pH activity of ibrexafungerp against fluconazole-susceptible and -resistant Candida isolates from women with vulvovaginal candidiasis. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.00562-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"5234_CR50","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0167-7012(00)00122-6","volume":"40","author":"S Stepanovic","year":"2000","unstructured":"Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M (2000) A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40(2):175\u2013179. https:\/\/doi.org\/10.1016\/s0167-7012(00)00122-6","journal-title":"J Microbiol Methods"},{"key":"5234_CR51","unstructured":"STI Treatment Guidelines. (n.d.). Retrieved May 18, (2026) from https:\/\/www.cdc.gov\/std\/treatment-guidelines\/"},{"key":"5234_CR52","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/142864","author":"C Tellapragada","year":"2014","unstructured":"Tellapragada C, Eshwara VK, Johar R, Shaw T, Malik N, Bhat PV, Kamath A, Mukhopadhyay C (2014) Antifungal susceptibility patterns, in vitro production of virulence factors, and evaluation of diagnostic modalities for the speciation of pathogenic Candida from blood stream infections and vulvovaginal candidiasis. J Pathog. https:\/\/doi.org\/10.1155\/2014\/142864","journal-title":"J Pathog"},{"issue":"4","key":"5234_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA (2021) Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep 70(4):1\u2013187. https:\/\/doi.org\/10.15585\/mmwr.rr7004a1","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"5234_CR54","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02119-18","volume":"63","author":"S Wring","year":"2019","unstructured":"Wring S, Borroto-Esoda K, Solon E, Angulo D (2019) SCY-078, a novel fungicidal agent, demonstrates distribution to tissues associated with fungal infections during mass balance studies with intravenous and oral [14C]SCY-078 in albino and pigmented rats. Antimicrob Agents Chemother 63(2):e02119-18. https:\/\/doi.org\/10.1128\/AAC.02119-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5234_CR55","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1111\/1567-1364.12042","volume":"13","author":"MJ Xiang","year":"2013","unstructured":"Xiang MJ, Liu JY, Ni PH, Wang S, Shi C, Wei B, Ni YX, Ge HL (2013) Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. FEMS Yeast Res 13(4):386\u2013393. https:\/\/doi.org\/10.1111\/1567-1364.12042","journal-title":"FEMS Yeast Res"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-05234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-026-05234-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-026-05234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:43Z","timestamp":1791673543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-026-05234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["5234"],"URL":"https:\/\/doi.org\/10.1007\/s00203-026-05234-5","relation":{},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the respective Institutional Ethics Committee. Informed Consent was obtained from all patients. Institutional Ethics Committee, PGIMER, Chandigarh, No. INT\/IEC\/2024\/SP2-1001 dated 30.08.2024. Research Ethics Board RIMS, Imphal, No. A\/206\/REB-Comm(SP)\/RIMS\/2015\/833\/174\/2022 dated 29.11.2022. Institutional Ethics Committee BHU, Varanasi, No. IMS\/IEC\/2024\/7332 dated 05.08.2024. Ethics and Scientific Review Committee, MGMMC, Indore, No. EC\/MGM\/Sept-23\/47 dated 11.09.2023.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"2"}}